Research & Education

IASLC European Webinar Series - 2015/2016 - Treatment of Squamous Cell NSCLC: What's New?

Thursday, March 10, 2016 - 7 p.m. Central European Time - Recording Available
Giorgio Scagliotti

Giorgio V. Scagliotti, MD
University of Torino
Professor of Medical Oncology
Department of Oncology

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD –Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

Name of Planner(s): 

 

   Deb Whippen-Nothing to Disclose

Name of Activity: 

 

Treatment of Squamous Cell NSCLC: What's New?

Date of Activity:

 

March 10, 2016

Faculty/Speaker(s):

Financial DISCLOSURES

COI Resolution:

 

 

Giorgio V. Scagliotti, MDSpeaker- Nothing to Disclose

Franco Foti- Moderator- Nothing to Disclose

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)xxxx

 Internet Enduring Material

Are there Commercial Supporters for this activity?

                 No

If yes, please list:

 

Currently, the standard first-line treatment option for squamous cell NSCLC is cytotoxic chemotherapy (including cisplatin or carboplatin) and a third-generation agent such as gemcitabine, taxanes, or vinorelbine. Targeted therapies have been tested in combination with cytotoxic chemotherapy but outcomes have been disappointing because of increased toxicity or lack of efficacy. Bevacizumab is contraindicated in patients with squamous histology tumours owing to a prohibitively high rate of severe pulmonary haemorrhage associated with bevacizumab treatment.

Recently, immune checkpoint inhibitors (e.g. anti-CTLA-4: ipilimumab; anti-PD-1: nivolumab and MK-3475; and anti-PD-L1: MPDL3280A) have emerged as new therapeutic options. Additionally,in the REVEL trial, ramacirumab improved overall survival in combination with docetaxel compared with docetaxel alone in the second-line setting of NSCLC.

In this online educational presentation, we examine data from recent clinical trials and consider how these data may contribute toward the development of a new treatment paradigm for squamous NSCLC.

Following the didactic presentation Dr. Scagliotti will address questions from the audience. There will be ample opportunity for discussion and comments. Attendees may submit questions and comments to the faculty via Internet chat.

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

 

After participating in this activity learners will be able to:

1. Identify the standard first-line treatment option for squamous cell NSCLC is cytotoxic chemotherapy (including cisplatin or carboplatin) and a third-generation agent such as gemcitabine, taxanes, or vinorelbine

2.Analyze targeted therapies have been tested in combination with cytotoxic chemotherapy but outcomes have been disappointing because of increased toxicity or lack of efficacy

3.Examine data from recent clinical trials and consider how these data may contribute toward the development of a new treatment paradigm for squamous NSCLC.

 

CME INFORMATION:

Financial/Commercial Relationships DISCLOSURES

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

Currently, the standard first-line treatment option for squamous cell NSCLC is cytotoxic chemotherapy (including cisplatin or carboplatin) and a third-generation agent such as gemcitabine, taxanes, or vinorelbine. Targeted therapies have been tested in combination with cytotoxic chemotherapy but outcomes have been disappointing because of increased toxicity or lack of efficacy. Bevacizumab is contraindicated in patients with squamous histology tumours owing to a prohibitively high rate of severe pulmonary haemorrhage associated with bevacizumab treatment.

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Thank you for your participation.

DOWNLOAD RECORDING

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

Participants who complete a post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar. If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program.

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME credit is only available to attendees of the live webinar.

Location Local time Time zone UTC offset
New York (U.S.A. - New York) Thursday, March 10, 2016 at 1:00:00 PM EST UTC-5 hours
Rome (Italy) Thursday, March 10, 2016 at 7:00:00 PM CET UTC+1 hour
London (United Kingdom) Thursday, March 10, 2016 at 6:00:00 PM GMT UTC
Paris (France) Thursday, March 10, 2016 at 7:00:00 PM CET UTC+1 hour
Madrid (Spain) Thursday, March 10, 2016 at 7:00:00 PM CET UTC+1 hour
Berlin (Germany) Thursday, March 10, 2016 at 7:00:00 PM CET UTC+1 hour
Prague (Czech Republic) Thursday, March 10, 2016 at 7:00:00 PM  CET UTC+1 hour
Dublin (Ireland) Thursday, March 10, 2016 at 6:00:00 PM GMT UTC
Amsterdam (Netherlands) Thursday, March 10, 2016 at 7:00:00 PM CET UTC+1 hour
Moscow (Russia) Thursday, March 10, 2016 at 9:00:00 PM MSK UTC+3 hours
Corresponding UTC (GMT) Thursday, March 10, 2016 at 6:00:00 PM     

How to use the Time Zone Converter